Signs of neuromuscular disorders that must not be missed

metabolize drugs pdf

0-9

Signs of neuromuscular disorders that must not be missed

NeuroFlash

NeuroFlash 1
Neurotoxicology

NeuroFlash 2
Neurologic disease in women
• WHIMS (estrogen or estrogen/progest)

NeuroFlash 3
Women and epilepsy

NeuroFlash 4
Neuro-oncology

NeuroFlash 5
Advances in Neurosurgery
• Microdialysis – cerebral metabolism

NeuroFlash 6
Neurology and the Military

NeuroFlash 7
Lifestyle factors in Alzheimers Disease

NeuroFlash 8
Epilepsy
• Failure of adequate trials of 2 tolerated and • Epilepsy Surgery seizure free (1 year)

NeuroFlash 9
Drug Induced Reversible Encephalopathy
• Tacrolimus, cyclosporine, sirolimus, MTX, interferom, rituximab, bevacizumab, sorafenib, sunitinib, fingolimod, IVIG • Cyclophosphamide, cytarabine, doxorubicin, etoposide, • Cocaine, ampetamines, TCA, SSRI, midodine, fludrocostisone

NeuroFlash 10
Neurologic Heavy Metal Disorders

NeuroFlash 11
Neurologic Autoimmune Encephalitis
• HA, fever, behavior change, psychosis, movement disorder,

NeuroFlash 12
Sleep disorders in children
• Down syndrome, muscular dystrophy, Prader-Willi

Source: http://www.geisinger.edu/Residencies/neurology/pdf/NeuroFlash_Hosey.pdf

sahealth.sa.gov.au

Sometimes the symptoms of urethritis may be slow The information contained within this publication is for to settle, or they may return after a week or two. general information only. Readers should always seek independent, professional advice where appropriate. If you have taken the antibiotics and have not had Royal Adelaide Hospital will not accept any liability sex, it is unlikely that an

Revisedtuberculosistreatmentguidelines2003-poster.p65

Tuberculosis Education Center/TB Elimination Division/Texas Department of Health Phone: (210) 534-8857 ext. 2489, Patient Information Fax: (210) 531-4500 Web Address: www.tdh.state.tx.us/tcid/TB-Education-Ctr.htm 1-800-TEX-LUNG Revised Tuberculosis Treatment Guidelines-2003 For additional information, refer to the printed guidelines. TABLE 2. DRUG REGIMENS FOR CULTURE-POSITIVE PULM